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Abstract  
Studies on trafficking of endogenous opioid receptors in vivo are subject of the present review.  
In many of the in vivo studies, the use of semi-quantitative immuno-electron microscopy is the 
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approach of choice.  Endogenous opioid receptors display differential subcellular distributions 
with µ opioid receptor (MOPR) being mostly present on the plasma membrane and δ- and κ-
opioid receptors (DOPR and KOPR, respectively) having a significant intracellular pool. 
Etorphine and DAMGO cause endocytosis of the MOPR, but morphine does not, except in some 
dendrites. Interestingly, chronic inflammatory pain and morphine treatment promote trafficking 
of intracellular DOPR to the cell surface which may account for the enhanced antinociceptive 
effects of DOPR agonists.  KOPR has been reported to be associated with secretory vesicles in 
the posterior pituitary and translocated to the cell surface upon salt loading along with the release 
of vasopressin. The study of endogenous opioid receptors using in vivo models has produced 
some interesting results that could not have been anticipated in vitro.  In vivo studies, therefore, 
are essential to provide insight into the mechanisms underlying opioid receptor regulation.  
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Introduction 
Opioid receptors belong to the seven-transmembrane receptor superfamily and are coupled with 
Gi/o proteins. Three types of opioid receptors have been cloned, µ- , δ- and κ-opioid receptor 
(MOPR, DOPR and KOPR, respectively).  
Opioid receptors can be activated by a variety of naturally occurring or synthetic opiates and 
several endogenous neuropeptides.  When the opioid receptors are activated upon binding of 
these ligands, a common regulatory event involves internalization of the receptor from the cell 
surface to intracellular sites. Agonist-induced endocytosis of opioid receptors has been studied 
extensively in cell models. Briefly, following binding of agonists to opioid receptors on plasma 
membranes, receptors undergo conformational changes leading to activation of G proteins and 
translocation of G protein-coupled receptor kinases to the cell surface resulting in 
phosphorylation of the receptors. β-arrestins are recruited to the phosphorylated receptors, which 
are subsequently endocytosed via a clathrin-dependent pathway. The decrease in the numbers of 
cell surface opioid receptors may be an adaptive process to avoid over-stimulation and may 
account in part for tolerance to opioids. Internalized opioid receptors are either recycled back to 
cell surface, resulting in re-sensitization of the receptors or sorted to degradation pathways, 
leading to down-regulation (Liu-Chen, 2004; von Zastrow et al., 2003).  
Like endocytosis, trafficking of opioid receptors to the cell surface may also be regulated. In 
dissociated dorsal root ganglion neurons, DOPR is sorted into large dense-core vesicles through 
interaction with protachykinin (Guan et al., 2005). Activation of surface DOPR causes elevation 
of intracellular Ca2+ mostly via an inositol triphosphate-dependent mechanism that results in 
insertion of large dense-core vesicles-associated DOPR onto the cell surface (Bao et al., 2003). 
Another mechanism leading to an increase of opioid receptors on the cell surface is the 
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pharmacological chaperone effects of opioid ligands. In cells transfected with opioid receptors, 
cell-permeant opioid ligands promote endoplasmic reticulum-to-Golgi trafficking of opioid 
receptors to enhance cell surface expression by facilitating correct folding of the newly 
synthesized receptors at the endoplasmic reticulum (Chen et al., 2006; Petaja-Repo et al., 2002; 
Wannemacher et al., 2007; Chaipatikul et al., 2003).  
Most studies on opioid receptor trafficking were carried out in various in vitro cell models. The 
limitations of these models are obvious, including differences in cellular milieu and receptor 
expression levels. In this review, observations regarding in vivo trafficking of opioid receptors 
will be presented. While some findings are consistent with in vitro results, others are 
unanticipated.      
 
Consideration of methods and approaches for subcellular localization of opioid receptors in 
vivo  
Each type of opioid receptor has a distinct distribution in the central nervous system as revealed 
by receptor autoradiography studies (Mansour et al., 1988) and immunohistochemical 
approaches (Arvidsson et al., 1995a, b). Some regions are abundantly enriched in opioid 
receptors and these include the striatum, the locus coeruleus, the ventral tegmental area and the 
dorsal horn of the spinal cords.  Therefore, these regions are commonly used for studies on 
endogenous opioid receptors.  
The use of receptor autoradiography and electron microscopy was employed in the 1980s and 
1990s (Moyse et al., 1997) where the opioid receptor ligands were labeled with 125I.  The 
localization of opioid receptors was detected using silver grains scattered by the radioactivity of 
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the bound radioligands.  Although a useful approach at the time, this technique fell out of favor 
with the availability of specific antibodies that recognize each type of opioid receptors.  
Immunohistochemistry combined with confocal microscopy is another useful approach. 
Although confocal microscopes are more accessible than electron microscopes in most 
laboratory settings, the resolution of the former is much lower than that provided by the latter. 
Combining transmission electron microscopy with immunogold or immunoperoxidase labeling 
provides a high-resolution technique for the study of the subcellular distribution of endogenous 
opioid receptors in brain tissue. Although a more sensitive labeling approach, immunoperoxidase 
labeling is not as readily quantifiable for subcellular distribution as the labeling tends to be 
diffuse and has propensity to adsorb to membrane structures (Novikoff et al., 1972). In contrast, 
immunogold labeling is quantifiable generally by counting the sliver grains. Therefore, 
immunogold labeling is a major approach to quantify the subcellular localization of opioid 
receptors.   
Importantly, it can not be over-emphasized that, with all immunohistochemical approaches, the 
validity of the results largely depends on the specificity and affinity of the antibodies. Specific 
antibodies recognizing each type of opioid receptors are available and have been characterized 
by different groups using complementary approaches. 
Additional approaches have been used to investigate trafficking of epitope-tagged receptors 
artificially introduced into animals. A mouse line expressing DOPR tagged with enhanced green 
fluorescent protein (EGFP) at the C-terminus has been established using the gene targeting 
approach and allows examination of whether there is a correlation between receptor trafficking 
and in vivo pharmacology end points (Scherrer et al., 2006). Generation of such a knock-in 
mouse line is time-consuming and costly.  
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In another approach, exogenous opioid receptors, with epitope tags, have been introduced into 
and expressed in certain brain regions by use of viral vectors (Haberstock-Debic et al., 2003). 
Trafficking studies is carried out in a more physiological environment than in primary neurons. 
This review does not cover the findings from such an approach. 
 
Differential subcellular localization of endogenous opioid receptors 
MOPR:   Several lines of evidence indicate that, irrespective of the brain region, the MOPR is 
mostly localized to plasma membranes (Fig. 1). For example, in the rat habenular nucleus, 
confocal microscopy has shown that MOPR immunoreactivity is associated primarily with 
plasma membranes of neurons (Keith et al., 1998). Using immunogold labeling combined with 
electron microscopy, Van Bockstaele and Commons (2001) showed that about 90% of MOPR 
immunoreactivity was located along the plasma membrane of somatodendritic processes in the 
rat locus coeruleus . MOPR has been shown to have a similar subcellular distribution in the 
striatal patches: 80% and 60% located on plasma membranes of dendritic spines and  axon 
terminals, respectively (Wang and Pickel, 2001). In the rat ventral tegmental area, immunogold 
labeled MOPR was seen on plasma membranes of dendrites and axon terminals (Garzon and 
Pickel, 2001). In the dorsal horn of rat spinal cord, most of the peroxidase-labeled MOPR was 
associated with postsynaptic membranes of dendrites (Wang et al., 2003).  Surprisingly, the 
majority of immunogold-labeled MOPR (> 70%) was found in cytoplasm of the dendrites of C1 
adrenergic neurons in the rat rostral ventrolateral medulla (Drake et al., 2005). It may reflect the 
differential subcellular distribution of MOPR in brain regions.  
DOPR:  In contrast to the high percentage of MOPR associated with neuronal membranes, 
DOPR immunolabeling is typically located intracellularly (Fig. 1). Electron microscopic analysis 
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revealed that 80-90% of immunogold-labeled DOPR was found within the cytoplasm of  rat 
spinal cord dorsal horn dendrites (Cahill et al., 2001a, b).  Further, this pattern is similar in 
striatal patches (Wang and Pickel, 2001) where the prevalence of the intracellular distribution is 
even more apparent in perikarya (Cahill et al., 2001a). In the ventral division of the reticular oral 
pontine nucleus of the cat, the majority of DOPR  immunoreactivity was located in the 
cytoplasm of dendrites (79%), axons (81%) and somata (Alvira-Botero and Garzon, 2006). In the 
rat and monkey dorsal root ganglia and dorsal horn, immunogold-labeled DOPR was frequently 
associated with the membranes of large dense-core vesicles (Zhang et al., 1998).  
In knock-in mice expressing DOPR-EGFP, quantitative analysis of confocal images indicates 
that ~ 60% of DOPR-EGFP is present on the cell surface in the striatum (Scherrer et al., 2006).  
It is noteworthy that the Bmax of [3H]naltrindole binding to DOPR in DOPR-EGFP knock-in mice 
is twice as high as that in wild type mice. In addition, fusion of the DOPR at the C-terminus with 
EGFP may affect interactions of the DOPR with associated proteins. These two factors may 
affect expression, subcellular localization and trafficking of DOPR-EGFP.  
KOPR:   A number of neuroanatomical studies have shown that the KOPR is primarily 
distributed intracellularly (Fig. 1), similar to the DOPR. Harris et al. (2004) reported that ~55% 
of KOPR immuoreactivity was located intracellularly in the dendrites of rat spinal cords of both 
sexes. In axon terminals, ~55% and 70% of KOPR immunoreactivity was intracellular in male 
and female rats, respectively. We observed an even higher percentage (~70%) of KORP 
immunoreactivity located intracellularly in the dendrites of male rat spinal cord (Wang et al., 
submitted). Most of intracellular KOPR was not associated with any discernable organelles, but 
some immunoreactivity was associated with mitochondria and endosomes. In the rat posterior 
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pituitary, ~60% of immunogold-labeled KOPR was associated with large secretory vesicles in 
the axon terminals and only ~11% with plasma membranes (Shuster et al., 1999).  
In contrast to its localization within dendrites, KOPR was frequently associated with small 
synaptic vesicles in axon terminals of the rat nucleus accumbens (Svingos et al., 1999, 2001; 
Meshul and McGinty, 2000). In addition, peroxidase-labeled KOPR immunoreactivity was 
detected along plasma membranes of presynaptic axon terminals, large dense-core vesicles and 
small vesicles of the hippocampus in guinea pigs (Drake et al., 1996).  When interpreting these 
results, one must take into consideration the known diffusion of peroxidase reaction products and 
their possible absorption to membrane structures that may lead to an overestimation of the 
association of KOPR immunoreactivity with plasma membranes and synaptic vesicle membranes.  
Consistent with this notion is the finding that when KOPR was labeled with peroxidase it was 
predominantly associated with plasma membranes of glial cells in rat medial prefrontal cortex,  
but when labeled with immunogold, KOPR was mainly in the cytosol (Svingos and Colago, 
2002).  
In summary, in vivo experimental approaches have provided valuable insight into the differential 
subcellular distributions of opioid receptors.  The predominance of MOPR on the cell surface 
and the greater prevalence of DOPR and KOPR intracellularly imply that the regulation of their 
trafficking is likely to be different.  
 
Trafficking of opioid receptors in vivo  
The studies on trafficking of opioid receptors in vivo are summarized in Table 1.  
MOPR:  It was first demonstrated in cell models that MOPR agonists had differential effects on 
internalization of the receptor. MOPR was internalized by acute treatment with enkephalins, 
 9 
etorphine or DAMGO, but not morphine (Arden et al., 1995; Keith et al., 1996). Agonist-
dependent internalization of MOPR has also been shown in tissues in vivo.  Systemic injections 
of etorphine caused rapid internalization of MOPR in neurons in the myenteric plexus of the 
guinea pig as demonstrated by immunohistochemistry and confocal microscopy (Sternini et al., 
1996). In contrast, acute morphine treatment (30 min) did not change localization of MOPR. 
Differential effects of etorphine and morphine on internalization of MOPR were also reported in 
neurons of the rat brain using the same approach (Keith et al., 1998). By counting the MOPR 
immunoreactive positive endosomes in confocal microscopy images, Trafton et al. (2000) 
reported similar findings for MOPR in the dorsal horn of rat spinal cord, which was internalized 
by DAMGO, remifentanil or endomorphin-1, but not morphine. Quantitative immunogold 
electron microscopy showed that acute etorphine treatment (15 min) significantly reduced the 
surface amount of MOPR in the dendrites in rat locus coeruleus (Fig. 1), whereas morphine, 
either acute (30 min) or chronic (5 days), had no effect (Van Bockstaele and Commons, 2001).   
In the dorsal horn of rat spinal cord, the endocytosed MOPR reappeared on cell surface within 60 
min (Trafton et al., 2000). The magnitude of MOPR internalization in lamina II interneurons 
induced by intrathecal DAMGO correlated with the extent of antinociception. However, such a 
correlation did not exist in morphine-tolerant rats. Although the antinociceptive effect of 
DAMGO was greatly decreased in morphine-tolerant rats, it promoted internalization of MOPR 
to a similar extent as in control rats (Trafton and Basbaum, 2004), indicating the desensitized 
MOPR retains the capability to be internalized. Surprisingly, although endogenous opioids are 
expected to be released upon application of noxious stimuli, no MOPR internalization was 
detected in lamina II neurons in nociception models, which may be due to inadequate amount of 
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the released endogenous opioids (Trafton et al., 2000). The findings prompted the authors to 
suggest that released opioid peptides may act presynaptically. 
Although morphine alone did not induce significant internalization of MOPR, morphine plus 
DAMGO, at a dose that did not cause endocytosis, internalized MOPR in the dorsal horns of rat 
spinal cord as demonstrated in confocal images. The combination also reduced the development 
of tolerance to chronic morphine treatment in rats (He et al., 2002). Recently, a knock-in mice 
expressing mutated MOPR with DOPR C-tail has been established (Kim et al., 2008). The 
mutant receptor in striatal neurons cultured from the knock-in mice were internalized by 
morphine in vitro; however, it was not examined in vivo. The knock-in mice showed 
significantly reduced tolerance and dependence to morphine (Kim et al., 2008). The authors 
concluded that these findings supported the notion that tolerance to opioid receptors is due to 
sustained activation of cell surface receptors.  
Interestingly, trafficking of endogenous MOPR upon acute morphine treatment appears to be 
compartment-specific. Haberstock-Debic et al. (2003) reported that in the rat nucleus accumbens, 
morphine (30 min) translocated MOPR to intracellular sites in dendrites, but not in neuronal cell 
bodies or axons. Drake et al. (2005) also observed that, in the rostral ventrolateral medulla, 
morphine induced internalization of MOPR in dendrites that had diameters <1.4 µm, but not in 
larger dendrites. These findings imply that the abundance of molecules involved in 
internalization machinery may vary in different compartments of neurons. The impact from 
surrounding environment or neural circuitries may also play a role.   
Confocal microscopy images showed that the endogenous MOPR1C, a splice variant  of MOPR, 
in lateral septum was internalized by morphine administered intracerebroventricularly in mice 
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(Abbadie and Pasternak, 2001), but MOPR was not. The difference in the C-terminal domains is 
likely to account for their different abilities to be internalized. 
Estrogen treatment also induced internalization of MOPR in medial preoptic nucleus and the 
posteriodorsal medial amygdala of ovariectomized rats when using the increase of the density of 
MOPR-immunoreactive fibers as an indicator for internalization (Eckersell et al., 1998). The 
internalization was rapid (within 30 min) and long lasting (>24 hr). The mechanisms underlying 
these observations are unknown. 
DOPR: In DOPR-EGFP knock-in mice, acute treatment with SNC80 caused significant 
internalization of DOPR in caudate putamen neurons in a dose-dependent manner, concomitant 
with an increase in locomotor activity. In addition, DOPR internalization correlated with the 
occurrence of desensitization to the subsequent application of SNC80 in enhancing locomotor 
activity (Scherrer et al., 2006).  
Since DOPR has a large intracellular pool, efforts were also devoted to investigating the stimuli 
that can promote cell surface expression of DOPR. Chronic inflammatory pain up-regulated 
mRNA and protein levels of DOPR in the dorsal horns of rat spinal cords, as demonstrated by in 
situ hybridization and immunoblotting (Cahill et al., 2003). Immunoelectron microscopy studies 
revealed that chronic inflammatory pain caused a significant increase of DOPR on the cell 
surface and in peripheral zones under plasma membranes, which may account for the increased 
antinociceptive efficacy of DOPR agonists in animals with chronic inflammatory pain (Cahill et 
al., 2003).  
Interestingly, chronic treatment with morphine promoted movement of intracellular DOPR to the 
cell surface in the dorsal horn of rat spinal cord as shown by quantitative immunoelectron 
microscopy (Fig. 1) (Cahill et al., 2001b). The effect of morphine was mediated by MOPR which 
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was shown by using MOPR blockade and MOPR knock-out mice (Morinville et al., 2003).  
Different from chronic inflammatory pain, morphine treatment regulated subcellular localization 
of DOPR without affecting overall expression level of DOPR (Cahill et al., 2001b).  
KOPR: Intrathecal injection of dynorphin A significantly decreased cell surface KOPR in the 
dorsal horns of rat spinal cord, but U50,488H did not, using quantitative immunoelectron 
microscopy (Wang et al., submitted). The differential effects of agonists may be due to the 
distinct receptor conformations they induce. However, the in vivo effect of dynorphin A is more 
complex. It has been reported that dynorphin A(2-17), the des-Tyr derivative of dynorphin A(1-
17), can activate NMDA (Vanderah et al., 1996) or bradykinin (Lai et al., 2006) receptors at high 
concentrations. It may also affect the trafficking of KOPR via neuronal circuitry.  
KOPR in the posterior pituitary is mostly associated with vesicles containing vasopressin 
(Shuster et al., 1999). When salt loading causes release of vasopressin, the KOPR is translocated 
to cell surface along with fusion of secretory vesicles with plasma membranes (Fig. 1) (Shuster 
et al., 1999). 
 
Comparisons between in vivo and in vitro studies 
MOPR: By and large, the results of the in vivo studies are similar to those of in vitro studies.  
Most of the MOPR is present on cell membranes in transfected cells and in neurons in vivo. 
DAMGO and etorphine cause significant internalization of MOPR, but morphine does not, both 
in vitro and in vivo. However, the in vivo study revealed that morphine promoted redistribution 
of endogenous MOPR in certain populations of dendrites. Its physiological significance is not 
clear at the present time.   
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DOPR and KOPR: While DOPR and KOPR expressed in cells are mostly localized on cell 
membranes, DOPR and KOPR in neuronal tissues in vivo are largely intracellularly located. 
There are several possibilities for the differences.  It may be due to differences in cellular milieu 
between cell lines and neurons in the brain and spinal cord, including proteins involved in their 
trafficking and interacting proteins. In addition, immunohistochemistry for KOPR and DOPR in 
vitro was mostly performed with antibodies against an epitope tag added to the N-termini of the 
receptors, whereas in vivo studies were conducted with DOPR and KOPR antibodies against N- 
or C-terminal domain of the receptors. Antibodies against different epitopes may not recognize 
intracellular and cell surface receptors equally, thus producing different subcellular distribution 
patterns. Indeed, Cahill et al. (2001a) reported that antibodies directed against a C-terminal 
domain peptide of the DOPR recognized predominantly cell bodies and proximal dendrites, 
whereas those directed against an N-terminal domain peptide, labeled extensively dendritic and 
terminal arbors besides cell bodies. In addition, electron microscopy studies revealed that the two 
antibodies label differentially with antibodies against the C-terminal peptide staining twice as 
many DOPR-immunoreactivities on membranes compared to those against the N-terminal 
peptide.  Moreover, when the receptor was epitope-tagged with FLAG, in most cases it contained 
a signal peptide to enhance endoplasmic reticulum membrane insertion and thus expression on 
plasma membranes (Guan et al., 1992), which may contribute to the differences.   
Since DOPR has a dramatic difference in localization between in vitro and in vivo, the in vivo 
studies are focused on how intracellular DOPR is promoted to the cell surface, whereas the in 
vitro investigations have been on agonist-induced internalization and trafficking of internalized 
receptors.  
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For the KOPR, the in vivo studies are consistent with several in vitro findings that U50,488H did 
not internalize rat KOPR in cells (Li et al., 1999; Zhang et al., 2002).   
 
Future studies  
The in vivo studies have provided many descriptive observations.  However, there is an obvious 
lack of mechanistic studies.  
Functional consequence of receptor trafficking in vivo:  Scherrer et al. (2006) have 
demonstrated in DOPR-EGFP mice that SNC80 enhances DOPR internalization in caudate 
putamen neuron, which renders the animals less sensitive to the subsequent SNC80 
administration (see above). In addition, Cahill et al. (2003) reported that inflammatory pain 
promoted trafficking of DOPR to cell surface in dorsal horn of the rat spinal cord, leading to 
enhanced response to DOPR agonists. More studies are needed to address the functional 
significance of MOPR and KOPR trafficking in vivo. McLaughlin et al. (2004) found that 
chronic U50,488H administration in mice enhanced KOPR phosphorylation and caused tolerance 
to KOPR-mediated antinociception. Whether the tolerance is related to KOPR internalization 
requires further study. 
 
Mechanisms underlying the differential subcellular distribution of endogenous opioid 
receptors: Although the three opioid receptors are highly homologous in their amino acid 
sequences, in neuronal tissues MOPR is mostly on cell surface, whereas DOPR and KOPR are 
predominantly intracellular. Since their sequences in the C-terminal domains are highly 
divergent, it is tempting to speculate that the differences in this region result in their interactions 
with different proteins, which play an important role in their subcellular localization. However, 
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the majority of a mutated MOPR with the C-terminal domain replaced with that of the DOPR 
was still found on cell surface in primary neurons cultured from the knock-in mice (Kim et al., 
2008).  It will be interesting to directly examine the subcellular distribution of these mutant 
receptors in vivo. Another possibility that can not be ruled out is that the differential distribution 
may result from the differential recognition of the antibodies. Therefore, it is critical to further 
characterize the subcellular localization of endogenous opioid receptors using antibodies against 
different epitopes.  
Drake et al.(2005) reported the majority of MOPR was located intracellularly in the dendrites of 
C1 adrenergic neurons in the rat rostral ventrolateral medulla, in contrast to other brain regions. 
Therefore, the differences in in vivo milieu, such as interacting proteins involved in trafficking, 
may lead to their differential subcellular distribution in brain regions. Identification of the 
interacting proteins that are involved in trafficking may help to elucidate the differences.  
Constitutive internalization and recycling of endogenous opioid receptors may affect their 
subcellular distribution. It has been reported that opioid receptors were differentially regulated in 
the trafficking pathways in vitro. While internalized MOPR is mostly recycled, the majority of 
endocytosed DOPR is sorted to lysosomes for degradation (von Zastrow et al., 2003). 
Antagonists can be used to stop constitutive internalization and their effects on subcellular 
localization of the receptors can be examined. 
Most receptors in transfected cells appear to be on cell surface; therefore, the in vitro systems do 
not always reflect the in vivo situations. One important task is to establish an in vitro system in 
which subcellular distributions of opioid receptors mimic those in tissues. Kim and von Zastrow 
(2003) found that treatment of PC12 cells with nerve growth factor caused cell differentiation 
and retained the transfected DOPR intracellularly; whereas transfected MOPR is mostly on cell 
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surface. This may be a good in vitro system that allows studies on mechanisms underlying 
differential subcellular distribution.  
Mechanisms underlying the compartment-selective internalization of MOPR by morphine: 
MOPR is internalized by morphine treatment in vitro when G protein-coupled receptor kinase 2 
is over-expressed (Zhang et al., 1998). It is possible that different compartments of neurons may 
have distinct compositions and/or abundance of internalization machinery components. In 
addition, we have reported previously that MOPR displayed differential glycosylation in 
different brain regions (Huang et al., 2008). Thus, it will be interesting to examine if the MOPR 
in different neuronal compartment may have distinct post-translational modifications.     
Mechanisms underlying the promotion of intracellular DOPR to the cell surface: Morphine 
treatment enhances cell surface level of endogenous DOPR and the MOPR is required for this 
action. Mechanisms for this process are not clear. MOPR and DOPR have been demonstrated to 
form dimers in vitro (George et al., 2000; Gomes et al., 2000); however, there is no definitive 
evidence showing their in vivo dimerization. It will be interesting to study if MOPR-DOPR 
dimerization is involved. Unfortunately, there are no reagents that can promote or block 
dimerization of MOPR-DOPR. Alternatively, morphine may act on the MOPR via neuronal 
circuitry and ultimately leads to enhancement in cell surface expression of the DOPR. If this is 
the case, the neuronal circuitry needs to be identified. 
Chronic inflammation also enhances cell surface DOPR. Biochemical processes leading to the 
enhancement remains to be determined. It is likely that chemical mediators of inflammation and 
subsequent activation of their receptors and down-stream effectors may be involved.  
Functional significance of intracellular pool of KOPR: KOPR has a large intracellular pool in 
dorsal horns of the rat spinal cord, which was mostly dispersed in the cytosol without association 
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with any organelles.  It will be interesting to investigate whether the intracellular KOPR can be 
translocated to cell surface under certain physiological or pathophysiological conditions.  
Infusion of U69,593, a selective KOPR agonist, to rostral ventromedial medulla produced 
antinociceptive effects against chemical or mechanical stimuli (Schepers et al., 2007). The 
efficacy of U69,593 was significantly enhanced in animals that had chronic inflammatory pain 
induced by hind paw injection of complete Freund's adjuvant. The presence of KOPR in rostral 
ventromedial medulla has been reported (Drake et al., 2007). Whether the enhanced efficacy of 
U69,593 is due to the increase in the number of cell surface KOPR and/or down-stream signaling 
needs further investigation.  
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Figure Legend 
Fig. 1 Illustration of electron microscopy findings on subcellular distribution of 
endogenous opioid receptors and their trafficking upon stimulation in vivo.  
Upper panel, MOPR is predominantly present on cell surface. MOPR is internalized following 
treatment with etorphine or DAMGO, but not morphine, in spinal cord, myenteric plexus and 
several brain regions. Morphine causes internalization of MOPR in the dendrites, but not in the 
cell body, in the nucleus accumbens.  
Middle panel, DOPR is mostly intracellular. Pretreatment with morphine or chronic 
inflammatory pain enhances trafficking of intracellular DOPR to cell surface in the spinal cord.  
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Lower panel, KOPR has a significant intracellular pool. In the posterior pituitary, salt loading 
promotes the insertion of KOPR on vasopressin-containing vesicles into cell surface of axon 
terminals. 
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Table 1. Summarization of in vivo trafficking of endogenous opioid receptors 
Receptor Method Animal Region Stimulation Findings Reference 
guinea pig myenteric plexus acute etorphine or  
morphine  
internalized by 
etorphine, but not 
by morphine 
(Sternini et 
al., 1996) 
rat dorsal horn of 
spinal cord 
DAMGO, 
remifentanil,  
endomorphin-1 or 
morphine; noxious 
stimuli 
internalized by 
DAMGO, 
remifentanil, 
endomorphin-1, but 
not by morphine or 
noxious stimuli 
(Trafton et 
al., 2000) 
morphine 
tolerant rat 
dorsal horn of 
spinal cord 
DAMGO DAMGO caused 
similar magnitudes 
of internalization in 
control and tolerant 
rats 
(Trafton and 
Basbaum, 
2004) 
rat dorsal horn of 
spinal cord 
DAMGO (low 
dose that did not 
promote 
internalization) + 
Morphine   
Promoted 
internalization 
(He et al., 
2002) 
rat Lateral septum acute morphine MOPR1C 
internalized 
(Abbadie 
and 
Pasternak, 
2001) 
immunohistochemi
stry + confocal 
microscopy 
OVX rat medial preoptic 
nucleus;  
posterodorsal 
medial amygdale 
estrogen internalization (Eckersell et 
al., 1998) 
locus coeruleus acute etorphine or  
morphine 
internalized by 
etorphine, but not 
by morphine 
(Van 
Bockstaele 
and 
Commons, 
2001) 
nucleus 
accumbens 
acute morphine internalized in 
dendrites, but not in 
cell bodies  
(Haberstock
-Debic et 
al., 2003) 
MOPR 
immunogold-
labeling + 
electronmicroscopy 
 
rat 
 
rostral 
ventrolateral 
medulla 
acute morphine internalized only in 
the dendrites with 
diameter <1.4 µm 
(Drake et 
al., 2005) 
confocal 
microscopy 
knock-in 
mouse 
striatum SNC80 internalization 
correlated with 
tolerance 
(Scherrer et 
al., 2006) 
Chronic 
inflammatory pain 
up-regulation and 
translocation to 
surface 
(Cahill et 
al., 2003) 
DOPR 
immunogold-
labeling + electron 
microscopy 
 
rat 
 
dorsal horn of 
spinal cord 
Chronic morphine 
treatment 
translocation to 
surface 
(Cahill et 
al.,2001b) 
dorsal horn of 
spinal cord 
U50,488H or 
dynorphin A 
internalized by 
dynorphin A 
(Wang et al. 
submitted) 
KOPR immunogold-
labeling + electron 
microscopy 
 
rat 
hypothalamus salt loading inserted into cell 
surface 
(Shuster et 
al., 1999) 
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